Pluristem Therapeutics Inc. news

   Watch this stock
Showing stories 1 - 10 of about 35   

Articles published

PSTI 2.75 -0.03 (-1.04%)
price chart
Morning Alert : Pluristem Therapeutics, Inc. (NASDAQ:PSTI), CBD Energy ...
On July 31, 2014 Pluristem Therapeutics, Inc. (NASDAQ:PSTI), a leading developer of placenta-based cell therapies, announced today that it has completed the approval process and received final clearance from a fifth regulatory agency for its 3D cell ...
News Buzz: Pacific Biosciences of California (NASDAQ:PACB), Pluristem ...
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) on Wednesday closed at $2.82. Stock institutional ownership is 1.50% while insider ownership includes 0.40%.
Morning Buzz: OXiGENE (NASDAQ:OXGN), Pluristem Therapeutics (NASDAQ ...
On 26 AUG OXiGENE, Inc. (NASDAQ:OXGN) announced that David Chaplin, Ph.D., CEO, will present a corporate overview at the Rodman and Renshaw Annual Global Investment conference on Tuesday, September 9, 2014 at 1:15 p.m.
Today's Stocks: Pluristem Therapeutics (NASDAQ:PSTI), Xilinx Inc. (NASDAQ ...
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) ended up at $2.65 in last trading session. Company distance from 20-day simple moving average (SMA20) is -2.09% while its monthly performance stands at -8.62%.
Investors Alert: Conversant (NASDAQ:CNVR), Dresser-Rand (NYSE:DRC ...
On 22 JULY Pluristem Therapeutics, Inc. (NASDAQ:PSTI) said that shares of Pluristem Therapeutics, Inc.
Hot Watch List : Hewlett-Packard Company (NYSE:HPQ), InterMune (NASDAQ ...
Pluristem Therapeutics Inc. (NASDAQ:PSTI) a leading developer of placenta-based cell therapies, announced that it has completed the approval process and received final clearance from a fifth regulatory agency for its 3D cell therapy manufacturing ...
Related articles »  
Best Stocks : Tesla Motors Inc (NASDAQ:TSLA), GrubHub Inc. (NYSE:GRUB ...
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) increased 1.81% to close at $2.82 on 27 August. Its return on assets (ROA) is -39.40% while return on investment (ROI) is -38.60%.
Watch List: Verizon Communications Inc. (NYSE:VZ), CGI Group (NYSE:GIB ...
Pluristem Therapeutics Inc. (NASDAQ:PSTI) a leading developer of placenta-based cell therapies, on 8 July announced the initiation of South Korean sites in the Phase II study assessing PLacental eXpanded (PLX) cells in the treatment of intermittent ...
Related articles »  
Market Movers : Relypsa, Inc. (NASDAQ:RLYP), Kinross Gold Corporation ...
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) has 0.40% insider ownership while its institutional ownership stands at 1.50%.
Related articles »  
Eye Catching Stocks: Himax Technologies (NASDAQ:HIMX), Arotech ...
Pluristem Therapeutics Inc. (NASDAQ:PSTI) a leading developer of placenta-based cell therapies, on 8 July announced the initiation of South Korean sites in the Phase II study assessing PLacental eXpanded (PLX) cells in the treatment of intermittent ...